Advertisement
Cancer Biology and Signal Transduction

Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells

Weiguo Zhang, Vivian R. Ruvolo, Chen Gao, Liran Zhou, William Bornmann, Twee Tsao, Wendy D. Schober, Paul Smith, Sylvie Guichard, Marina Konopleva and Michael Andreeff
DOI: 10.1158/1535-7163.MCT-13-0576 Published July 2014

Abstract

Aberrant activation of multiple signaling pathways is common in acute myelogenous leukemia (AML) cells, which can be linked to a poor prognosis for patients with this disease. Previous research with mTOR or MEK inhibitors revealed cytostatic, rather than cytotoxic, effects in in vitro and in vivo AML models. We evaluated the combination effect of the mTOR inhibitor AZD8055 and the MEK inhibitor selumetinib on human AML cell lines and primary AML samples. This combination demonstrated synergistic proapoptotic effects in AML cells with high basal activation of MEK and mTOR. We next incorporated the BH3 mimetic ABT-737 into this combination regimen to block Bcl-2, which further enhanced the apoptogenic effect of MEK/mTOR inhibition. The combination treatment also had a striking proapoptotic effect in CD33+/CD34+ AML progenitor cells from primary AML samples with NRAS mutations. Mechanistically, upregulation of the proapoptotic protein Bim, accompanied by the downregulation of the antiapoptotic protein Mcl-1 (mainly via protein degradation), seemed to play critical roles in enhancing the combination drug effect. Furthermore, the modulation of survivin, Bax, Puma, and X-chromosome-linked inhibitor of apoptosis protein (XIAP) expression suggested a role for mitochondria-mediated apoptosis in the cytotoxicity of the drug combination. Consequently, the concomitant blockade of prosurvival MEK/mTOR signaling and the deactivation of Bcl-2 could provide a mechanism-based integrated therapeutic strategy for the eradication of AML cells. Mol Cancer Ther; 13(7); 1848–59. ©2014 AACR.

Introduction

Aberrant gene expression/signaling pathways like the RAS/Raf/MAPKMEK/ERK and the PI3K/Akt/mTOR pathways can promote tumorigenesis in many tissues, including the hematopoietic system. Indeed, the deregulation of RAS/Raf/MEK/ERK or PI3K/Akt/mTOR signaling has been shown to contribute to leukemogenesis (1–3), and the NRAS-activating mutations, which abnormally stimulate RAF/MEK/ERK and PI3K/AKT/mTOR, are found in about a third of hematopoietic malignances, including acute myelogenous leukemia (AML; ref. 1). Furthermore, we have previously reported that the simultaneous activation of the aforementioned signaling pathways is consistently associated with poor disease prognosis in patients with AML (4).

In several studies by our group and others, the MEK inhibitors CI1040 and selumetinib (also known as AZD6244) exerted mainly cytostatic effects in in vitro and in vivo AML models. This was also the case for the mTOR inhibitors CCI779 and RAD001 (5–7). Thus, interrupting one of these signaling pathways independently seems to be insufficient to trigger cell death in AML cells (5, 8, 9).

The B-cell lymphoma 2 (Bcl-2) family of proteins are key regulators of cancer cell apoptosis. The antiapoptotic Bcl-2 proteins Bcl-2, Bcl-xL, and myeloid cell leukemia sequence 1 (Mcl-1) prevent cellular apoptosis via their expression and dimerization with the proapoptotic Bcl-2 proteins Bim and Bax. The overexpression of the antiapoptotic Bcl-2 proteins correlates with an overall lower overall survival rates for patients with AML (10, 11). Several small-molecule Bcl-2 inhibitors have been developed, and they have shown encouraging single-agent activity in preclinical and clinical trials (12, 13). We hypothesize that the concomitant blockade of the MAPK and mTOR signaling, in conjunction with interference with antiapoptotic Bcl-2 family members, could promote marked cytotoxic activity in AML cells, including AML stem cells. The purpose of this study was to determine if, and by what mechanisms, the cosuppression of MEK and mTOR signaling in concert with the interruption of antiapoptotic Bcl-2 family members could effectively induce apoptosis in AML cells. We examined a three-drug combination consisting of the mTOR inhibitor AZD8055, the MEK inhibitor selumetinib, and the antiapoptotic Bcl-2 family mimetic ABT-737 on human AML cells and primary AML samples. This combination demonstrated marked proapoptotic effects in AML cells with high basal activation of MEK and mTOR. The rationale for this combination treatment was based on (i) the ability to disable Mcl-1–mediated resistance associated with the inhibition of pERK, (ii) overcoming resistance to MEK inhibition mediated by constitutive and reactive PI3K/AKT in AML cells (12, 14), and (iii) by mediating loss of mitochondrial inner transmembrane potential in the presence of Bcl-2 antagonist ABT-737. Our results suggest that this drug combination can be potentially effective in eradicating AML cells, and, as such, could be an important strategy for controlling AML in vivo.

Materials and Methods

Reagents and antibodies

Selumetinib (also known as AZD6244 and ARRY-142886) and AZD8055 were provided by AstraZeneca. ABT-737 was synthesized at the University of Texas MD Anderson Cancer Center based on its published chemical structure (15). The chemical structures of the above-mentioned reagents are shown in Supplementary Fig. S1. Antibodies against human phosphorylated (p)-p44/42 MAPK (ERK1/2)(Thr202/Tyr204), p-AKT(Ser473), p-AKT(Thr308), p-S6K(Ser240/244), p-Rb (Ser780), p-4E-BP1 (Thr37/46), p-Bad (Ser136), p-MEK1/2 were purchased from Cell Signaling Technology, as were the antibodies against AKT, S6K, 4E-BP1, Bad, Bid, Bcl-xL, survivin, caspase-8, caspase-9, and cleaved caspase-3. Antibodies against Bax, Mcl-1, X-chromosome-linked inhibitor of apoptosis protein (XIAP), and p27Kip-1 were purchased from BD Biosciences; antibody against Bcl-2 was purchased from Dako; antibody against Bak was purchased from Upstate; antibodies against ERK2, Cdk2, and Cdk4 were purchased from Santa Cruz Biotechnology; and antibodies against Bim, cyclin D1, Cdc2, and Puma were purchased from CalBiochem.

AML cell lines and patient samples

The human AML cell lines U937, KG-1, and MV4-11 were obtained from the ATCC. The OCI/AML3 cell line was kindly provided by Dr. M. Minden (Princess Margaret Hospital, Toronto, Ontario, Canada). The MOLM13 cell line was obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen. U937, KG-1, MOLM13, and OCI/AML3 cells were validated in September 2010 by short tandem repeat DNA fingerprinting using the AmpFlSTR Identifier Kit according to the manufacturer's instructions (Applied Biosystems). Genetic characteristics of AML cell lines used in this study are summarized in Supplementary Table S1.

Peripheral blood and bone marrow samples were obtained from patients with newly diagnosed, relapsed, or refractory AML after written informed consent had been obtained from each patient according to institutional guidelines of the University of Texas MD Anderson Cancer Center. All cells, including those obtained from peripheral blood and bone marrow samples, were cultured in RPMI 1640 culture medium supplemented with 10% fetal calf serum.

Cell viability and apoptosis assays

Cell viability was assessed using an automated cell counter employing the Trypan blue dye exclusion method, and cell apoptosis was examined by flow cytometry as described previously (16). To evaluate apoptosis induction by treatment with AZD8055 plus selumetinib in 2 sets of peripheral blood and bone marrow samples (with and without NRAS mutations), mononuclear cells were separated by Ficoll–Hypaque density-gradient centrifugation (Sigma Chemicals). Apoptosis of bulk leukemic and leukemic progenitor cells (i.e., gating the AML cells with CD34+ or CD33+) was determined as described above. Induction of specific apoptosis was calculated using the following formula: specific apoptosis (%) = 100 (drug-induced apoptosis − spontaneous apoptosis)/(100 − spontaneous apoptosis) (see ref. 17).

Cell proliferation assay

AML cells were treated with the indicated agent for 24 hours, and bromodeoxyuridine (BrdUrd; BD Pharmingen) was added to the medium at the last 45 minutes of treatment to allow BrdUrd incorporation into newly synthesized cellular DNA. The cells were harvested and fixed in 70% cold ethanol, and BrdUrd was labeled with an anti–BrdUrd-fluorescein isothiocyanate antibody and measured using flow cytometry (18).

Immunoblot and immunoprecipitation analyses

AML cells were treated with AZD8055, selumetinib, or ABT-737 alone or in combination as indicated and then collected for analysis. Semiquantitative immunoblotting data were generated using the Scion imaging software program (Beta version 4.03; Scion; ref. 18).

For the immunoprecipitation studies, AML cells were lysed and the cell lysates (containing ∼0.5 mg of total protein in each sample) were incubated overnight with a primary anti–Bcl-2 antibody. Protein A/G PLUS-agarose (Santa Cruz Biotechnology) was added to the lysis buffer for an additional 4 hours of incubation at 4°C. Bcl-2 family proteins were resolved using SDS–PAGE. The amount of Bax bound to Bcl-2 was determined using immunoblotting analysis with an anti-Bax antibody.

Knockdown of Bim or Mcl-1 protein

Bim protein was knocked down by transfecting siRNAs (sequence: 5′-GACCGAGAAGGUAGACAAUUGdTdT-3′) and mock control siRNAs (Dharmacon RNAi Technologies) into OCI/AML3 and U937 leukemia cells using an electroporation method (T-solution, X-001 and C-solution, W-001, respectively; Amaxa Biosystems) following the manufacturer's instructions. The final concentration of siRNA in the electroporation buffer was 200 nmol/L.

Mcl-1 protein was knocked down by lentiviral transfection with a gene-specific shRNA transfer vector targeting residues 2421–2440 on RefSeq NM_021960.4. Lentivirus was prepared by cotransfection of HEK293T cells (ATCC) with an equal molar mix of transfer vector and packaging plasmids (psPAX2 and pMD2.G; plasmids 12260 and 12259, respectively, from Addgene) using JetPrime transfection reagent as directed in the manufacturer's instructions (Polyplus). The OCI/AML3 cells underwent lentivirus transfection with Mcl-1 shRNA vector or nonspecific control vector (pLKO.1 TRC control, plasmid 10879; Addgene) and selected with puromycin (Invitrogen) starting at 0.5 μg/mL. Knockdown was verified by immunoblot analysis and real-time PCR.

Real-time PCR assays

The OCI/AML3 and MOLM13 cells were treated with the indicated drugs for 6 hours, and total RNA was extracted with Trizol (Life Technologies) following the manufacturer's protocol. cDNA was synthesized as described previously (19), and duplicated TaqMan gene expression assays were carried out in a 25-μL reaction containing the cDNA equivalent of 1.0 ng of total RNA with TaqMan gene expression assays (Life Technologies) for Mcl-1 (Hs03043899_m1), Bim (Hs00708019_s1), or housekeeping gene18S (Hs03928985_g1) using an ABI model 7900HT fast real-time PCR system. Data were analyzed by the ΔΔCt method using RQ Manager 1.2.1 software (Life Technologies), and the relative abundance of target in treated cells, normalized to that of vehicle treated cells, is reported as follows: RQ = 2 exp [−ΔΔCt], where ΔΔCt = ΔCttreated − ΔCtvehicle, and ΔCt = Ctgene of interest − Ct18S.

Establishment of NRAS-mutated leukemia cells

A plasmid harboring the NRAS cDNA (IMAGE:3826638; Open Biosystems) was used as a template to generate the NRAS open reading frame (ORF) flanked by NheI (5′) and XhoI (3′) sites by PCR with HiFi Hot Start polymerase (Kapa Biosystems) and the primers TGTGAAGCTAGCCGCCATGACTGAGTACAAACTGG (forward) and CCTCGAGTTACATCACCACACATGGCAATCCC (reverse). An expression vector with the NRAS cDNA was constructed by replacing the ORF for enhanced green fluorescent protein in EGFPc2 with the ORF for NRAS as a NheI-to-XhoI construction. This expression vector was used to generate the G12D mutant with a QuikChange II XL site-directed mutagenesis kit (Agilent Technologies) and the primers GTG GTG GTT GGA GCA GAT GGT GTT GGG AAA AGC GCA CTG AC (forward) and GTC AGT GCG CTT TTC CCA ACA CCA TCT GCT CCA ACC ACC AC (reverse). Lentiviral transfer vectors were then constructed by inserting the wild-type or mutant G12D between the NheI and NotI sites of pCDH-CMV-MSC-EF1-Puro (System Biosciences). The vectors were introduced into MV4-11 cells by lentiviral transduction as described (20). Positive cells were selected and maintained with puromycin (up to 1 μg/mL). NRAS activation was confirmed by measuring the phosphorylation level of MEK by immunoblotting.

Mitochondrial inner transmembrane potential (Δψm) analysis

MV4-11-NRAS-wild type and MV4-11-NRAS-mutated cells were treated with AZD8055, selumetinib, or ABT-737 alone or in combination as indicated for 24 hours and then collected for staining with CMXRos (300 nmol/L) and MitoTracker Green (100 μmol/L; both from Molecular Probes) for 1 hour at 37°C. The Δψm was determined using flow cytometry by measuring CMXRos retention (red fluorescence) while simultaneously adjusting for the mitochondrial mass (green fluorescence as described previously; ref. 21).

Statistical analyses

The Student t test was used to analyze immunoblot, cell growth, and apoptosis data. P values ≤ 0.05 were considered statistically significant. The Chou–Talalay method (22) was used to determine combination indices for the agents. A combination index value of 1 indicated an additive effect, <1 synergism, and >1 antagonism. The mean combination index values were calculated at different effect levels (50%, 75%, and 90% effective concentrations). All statistical tests were two-sided, and the results are expressed as the mean ± SD (error bars) of triplicate samples.

Results

Cotargeting of signaling pathways with AZD8055 and selumetinib enhanced the growth-inhibitory effect of either agent alone in AML cells

Targeted treatment with MEK inhibitor selumetinib or the allosteric mTOR inhibitors CCI779 or RAD001 had only limited effects in most leukemia cell lines in our previous studies (6, 7). Therefore, for the current study, we assessed the effect of combining selumetinib with the novel mTOR kinase inhibitor AZD8055 in AML cell lines. Synergistic effects on cell growth inhibition were observed with OCI/AML3, U937, or MOLM13 (Fig. 1A, Supplementary Fig. S2). AML cells that displayed synergistic effects in response to the combination treatment expressed relatively high levels of p-ERK and p-AKT (Fig. 1B). However, KG-1 cells lack detectable p-ERK and p-AKT and showed an antagonistic effect. Furthermore, the combination treatment notably suppressed the levels of ERK1/2 (Thr202/Tyr204) and AKT (Ser473) phosphorylation in the OCI/AML3, MOLM13, and U937 cells, but had no consistent effect on the phosphorylation of AKT Thr308 (Fig. 1C).

Figure 1.
Figure 1.

Dual blockade of mTOR/MEK signaling synergistically or additively inhibits growth in AML lines OCI/AML3, MOLM13, and U937, but not KG-1. A, AML cells were treated with AZD8055, selumetinib, or both at the indicated concentrations for 48 hours. Inhibition of cell growth was measured using viable cell counts as described in Materials and Methods, and expressed as the percentage of untreated cells. Data, the mean of four independent determinations. Error bars, 95% CIs. *, P < 0.05; **, P < 0.01; and ***, P < 0.001. B, basal expression levels of phosphorylated and total ERK, AKT, and Bcl-2 proteins was determined by immunoblotting. Numbers indicate ratio of phosphorylated proteins to the respective total proteins. C, AML cells were treated with AZD8055 and selumetinib at the indicated concentrations for 24 hours, and the profile of signaling and cell-cycle–related checkpoint proteins was measured by immunoblotting. α-tubulin was used as loading control. D, AML cells were treated with the indicated agents for 24 hours, and BrdUrd incorporation was determined using flow cytometry after labeling with anti–BrdUrd-fluorescein isothiocyanate antibody. Data, the mean of triplicate experiments.

We next measured BrdUrd incorporation by flow cytometry to determine whether the combination treatment affected cell-cycle progression. In all lines, cell-cycle progression was modestly impaired by the single and combination agent treatments as there were fewer cells in S-phase of the cell cycle compared with the controls (Fig. 1D). Although KG-1 cells lack detectable p-AKT and express only trace levels of p-ERK, approximately 50% of these cells were apparently blocked from entering S-phase by mTOR or combined inhibition compared with controls (Fig. 1D).

The KG-1 cells expressed p-S6K (Ser240/244), which was markedly suppressed by the combination treatment (Fig. 1C), suggesting that S6 protein may be critical in the G1–S-phase transition of the cell cycle. Interestingly, the expression of p-S6K, which is best known as a downstream target of PI3K/mTOR/AKT signaling rather than as a target of one of the MEK/ERK signaling cascades, decreased significantly when MEK signaling was suppressed by selumetinib only in OCI/AML3 and U937 cells, but not in MOLM13 or KG-1 cells. In contrast, the phosphorylation of eukaryotic initiation factor 4E-binding protein (4E-BP1), a downstream protein activated by mTORC1/S6K signaling (23), was inhibited by AZD8055 but not selumetinib in all four cell lines (Fig. 1C). Upregulation of the cell-cycle inhibitor p27Kip-1 and downregulation of the G1 phase–related checkpoint protein cyclin D1/cdk4 complexes were observed in all tested AML cell lines. However, downregulation of cdk2, cdc2, and p-Rb was generally observed in OCI/AML3, MOLM13, and U937 cells, but not in KG-1 cells, suggesting that these proteins may be not specific to the G1–S-phase transition of the cell cycle.

Blockade of mTOR/MEK signaling has synergistic cytotoxic effects that are associated with modulation of proapoptotic Bim and antiapoptotic Mcl-1 proteins

The AZD8055 and selumetinib agent combination produced synergistic proapoptotic effects in OCI/AML3, MOLM13, and U937 cells (Fig. 2A). In addition, in OCI/AML3, MOLM13, and U937 cells, the proapoptotic protein Bim was upregulated, and the antiapoptotic proteins Mcl-1, p-Bad(Ser136), and survivin were downregulated by AZD8055 and even more so by the combination with selumetinib (Fig. 2B). We also observed modulated expression of the p53-regulated proteins Puma and Bad in certain leukemia cell lines. However, no notable changes in the expression of Bcl-2, Bcl-xL, or Bax were observed. Of note, the upregulation of Bim expression and downregulation of Mcl-1 expression correlated with cleavage of caspase-3, implying that Bim and Mcl-1 play important roles in apoptosis induction. This combination was seemingly antagonistic in the KG-1 cells (Fig. 2A), which have a low basal level of ERK and AKT activation, and did not affect Mcl-1 expression in these cells (Fig. 2B).

Figure 2.
Figure 2.

Synergistic proapoptotic effects induced by blockade of mTOR/MEK signaling are associated with modulation of Mcl-1 and Bim. A, AMLcells were treated with AZD8055 (0.3 μmol/L), selumetinib (0.9 μmol/L), or both for 72 hours, and the percentage of apoptotic cells was determined using flow cytometry. B, Bcl-2 family proteins were assessed by immunoblotting after 24 hours of treatment with AZD8055 and selumetinib. The numbers below the blots indicate the ratio of protein to the loading control β-actin. C, OCI/AML3 and MOLM13 cells were treated with indicated inhibitors for 6 hours, and relative mRNA expression levels were determined by real-time PCR by calculating the ratios of Mcl-1/Bim to 18S mRNA. D, OCI/AML3 cells were treated for 48 hours in the presence or absence of cycloheximide (0.5 μmol/L), and apoptosis was determined by flow cytometry. Inset, protein levels of survivin, Mcl-1, and Bim after treatment of OCI/AML3 cells with cycloheximide (CHX) for 6 hours. *, P < 0.05; **, P < 0.01; and ***, P < 0.001; NS, no statistical significance.

We therefore suspected that the modulation of Mcl-1 and Bim levels might play a key role in the combination treatment–induced apoptosis. Further investigation of the mRNA transcription level showed that the combination upregulated Bim only in MOLM13, but not in OCI/AML3 cells. No statistically significant modulation was observed in Mcl-1 levels (Fig. 2C). We next treated OCI/AML3 cells in the presence of the protein translation inhibitor cycloheximide, which further induced apoptosis in the treatment groups (Fig. 2D). Cycloheximide treatment moderately decreased protein levels of Bim, but not of Mcl-1 after 6-hour exposure. (Fig. 2D, inset). On the other hand, suppression of protein degradation with proteasome inhibitors bortezomib or MG132 did not markedly influence the combination-induced cell apoptosis (Supplementary Fig. S3). Taken together, the combination-induced changes of Mcl-1 and Bim protein levels might result from translational, rather than transcriptional or proteasomal degradation, effects.

To further evaluate the roles of Bim and Mcl-1 in apoptosis induction, we silenced Bim expression with siRNA or Mcl-1 expression with shRNA and assessed apoptosis induction after treatment with AZD8055 and selumetinib for 48 hours. The knockdown of Bim markedly reversed the combination effect of apoptosis induction by the treatment with AZD8055 and selumetinib in OCI/AML3 (Fig. 3A) and U937 (Supplementary Fig. S4) cells, whereas the knockdown of Mcl-1 enhanced this effect in OCI/AML3 cells (Fig. 3B). These results suggested that Bim and Mcl-1 play opposite roles in apoptosis induction by this combination treatment in the AML cells.

Figure 3.
Figure 3.

Levels of proapoptotic BH3-only Bim protein and antiapoptotic Mcl-1 protein play a critical role in drug combination-induced apoptosis. A, OCI/AMl3 cells were electroporated with Bim siRNA or scrambled siRNA for 24 hours, treated with AZD8055 (0.4 μmol/L) and/or selumetinib (0.2 μmol/L) for 48 hours, and examined for apoptosis induction. Inset, knockdown of basal level of Bim protein expression. B, OCI/AML3 cells were transferred with Mcl-1 shRNA or shGFP control lentiviral vectors, the puromycin-selected cells were treated with AZD8055 (0.4 μmol/L) and/or selumetinib (0.4 μmol/L) for 48 hours, and examined for apoptosis induction. Inset, knockdown of basal level of Mcl-1 after puromycin selection. DMSO, control. *, P < 0.05; **, P < 0.01.

Interference with Bcl-2 protein dimerization enhanced apoptotic effects induced by combined AZD8055 and selumetinib in AML cells

Because the induction of apoptosis in leukemia cells is largely controlled by dimerization of proapoptotic and antiapoptotic proteins (11), we hypothesized that, in addition to the inhibition of mTOR/MEK signaling, the inhibition of binding of Bax or Bim with their respective partners, Bcl-2 and Bcl-xL, would further enhance apoptosis induction. We, and others, have reported previously that the Bcl-2 antagonist ABT-737 can bind to Bcl-2 family members resulting in leukemic cell death (12, 24). In addition, the expression level of the antiapoptotic Mcl-1 protein is inversely correlated with cell sensitivity to ABT-737 due to the inability of the latter to bind and inhibit Mcl-1 (12, 25). We tested the three-drug combination of ABT-737, AZD8055, and selumetinib at low concentrations (0.06, 0.1, and 0.3 μmol/L, respectively), and observed significantly enhanced proapoptotic responses in KG-1, OCI/AML3, and MOLM13 cells compared with ABT-737 only or with the AZD8055/selumetinib combination only (Fig. 4A). In the U937 cells which had the lowest basal level of Bcl-2 protein of the four AML cell lines tested (Fig. 1B), this drug combination did not induce marked apoptosis (Fig. 4A). However, apoptosis induction in the U937 cells could be boosted by increasing the concentrations of AZD8055 to 0.3 μmol/L and selumetinib to 0.9 μmol/L (Fig. 4B), suggesting that at higher doses of the mTOR inhibitors were still capable of inducing apoptosis in leukemic cells possessing a high basal level of p-AKT driven by PTEN deletion. Impressively, the KG-1 cells that were resistant to selumetinib and AZD8055 (Supplementary Figs. S5 and S6) demonstrated enhanced sensitivity to the three-drug combination after a 48-hour treatment (Fig. 4A).

Figure 4.
Figure 4.

ABT-737 further enhances the proapoptotic effect of the AZD8055/selumetinib combination treatment in AML cells. A, AML cells were treated with AZD8055, selumetinib, ABT-737, or the indicated combinations for 48 hours, and examined for apoptosis induction. B, U937 cells were treated as described above and examined for apoptosis induction. **, P < 0.01 and ***, P < 0.001. C, KG-1 and OCI/AML3 cells were treated with ABT-737, AZD8055 plus selumetinib, or both at the indicated concentrations (in μmol/L) for 6 hours, and Bcl-2 protein was pulled down with anti–Bcl-2 antibody–conjugated A/G beads. Bcl-2–binding Bax protein expression was measured using immunoblotting. A 10% Bcl-2 input of immunoprecipitated fractions is shown as a loading control for Bcl-2 protein level. IP, immunoprecipitation; WB, immunoblot. D, KG-1 and OCI/AML3 cells were treated with ABT-737, AZD8055 plus selumetinib, or both for 24 hours, and the cells were lysed to assess expression of apoptosis-related Bcl-2 family members in mitochondrial, cytosol, and whole-cell fractions via immunoblotting. Casp, caspase; EL, extra-long; L, long; and S, short.

We treated the ABT-737–sensitive KG-1 cells and ABT-737–resistant OCI/AML3 cells with ABT-737 alone or with AZD8055/selumetinib combination to gain an insight into the mechanism of apoptosis induction by the triple-drug combination treatment. An immunoprecipitation assay pull-down of the Bcl-2 complex with anti–Bcl-2 antibody indicated that Bcl-2/Bax heterodimerization was reduced in both cell lines after a 6-hour ABT-737 treatment, and even more markedly so in cells treated with all the three drugs (Fig. 4C). After a 24-hour combination treatment, we observed the cleavage of caspase-9, caspase-8, caspase-3, and Bid, cytochrome c release, and the localization of Bax to the mitochondria (Fig. 4D). Furthermore, Bax was upregulated resulting in an increased Bax:Bcl-2 ratio, and the expression of Mcl-1 and the XIAP was decreased possibly because of caspase-3–mediated cleavage. These findings suggested that ABT-737 enhances the proapoptotic effect of the AZD8055/selumetinib combination by interfering with Bcl-2 function, thus triggering mitochondria-mediated cell death.

Three-drug combination treatment exerted synergistic proapoptotic effects in AML blast cells with NRAS mutations

We next tested the three-drug combination on peripheral blood or bone marrow cells obtained from patients with AML (the patient cytogenetic characteristics are summarized in Supplementary Table S2). Because RAS mutation is known to activate both the MEK and mTOR pathways, we assessed apoptosis induction in these samples based on their NRAS mutational status. Selumetinib or AZD8055 alone induced modest apoptosis in five of seven samples harboring NRAS mutations (i.e., cases 3, 4, 5, 6, and 7; Fig. 5A), and in one sample with wild-type RAS that had an FLT3-ITD mutation (i.e., case 11; Fig. 5B). By comparison, the combination treatment with both agents enhanced apoptosis in most NRAS-mutated samples (except case 2; Fig. 5A), and in two of the seven NRAS wild-type samples (i.e., cases 11 and 13; Fig. 5B). Both of the latter cases harbored mutations of FLT3. Except for cases 1 and 3, ABT-737 was highly effective in inducing apoptosis in primary AML cells, and the combination of all three agents further induced apoptosis in bulk leukemic, as well as in CD34+/CD33+, cells in 12 of 14 patient samples. Overall, the specific apoptosis induction by the three-agent combination was higher in the CD33+/CD34+ AML progenitor cells of NRAS-mutated AML samples compared with those with NRAS wild type (P < 0.01; Fig. 5C). These results indicate that NRAS-mutated AML progenitor cells might be more dependent on MEK/mTOR signaling than NRAS wild-type cells.

Figure 5.
Figure 5.

Three-drug combination treatment exerts synergistic proapoptotic effects in AML blasts with NRAS mutations. Mononuclear cells obtained from peripheral blood and bone marrow samples of patients with AML with (A) or without (B) NRAS mutations were exposed to AZD8055, selumetinib, and/or ABT737 at the indicated concentrations (in μmol/L) for 24 to 72 hours. C, the specific apoptosis was determined in triplicate samples based on the triple-drug treatment data shown in Fig. 5A and 5B, and shown as a comparison between bulk and CD33+/34+ fractions of the NRAS-mutated and NRAS-wild samples. **, P < 0.01. D, AML patient sample (case 7) was treated with indicated concentration (μmol/L) of inhibitors for 24 hours, and correlative protein expression was determined by immunoblotting.

To confirm that these agents effectively blocked the corresponding signaling pathway in primary leukemia cells, we measured the p-ERK and p-AKT levels in one NRAS-mutated AML sample (case 7) using immunoblotting. The results indicated that targeting MEK or mTOR with the corresponding drugs or their combination markedly suppressed phosphorylation of ERK or AKT (Fig. 5D). The pattern of phosphorylation suppression of ERK/AKT correlated with apoptosis induction caused by these inhibitors (Fig. 5A, case 7).

Finally, we investigated the molecular mechanisms governing apoptotic cell death in the NRAS-mutant AML cells. We compared the modulation of the expression of the key apoptotic and signaling proteins in isogenic-paired NRAS wild-type and NRAS-mutated AML cells MV4-11. Compared with wild-type cells, cells with mutant NRAS were considerably more sensitive to treatment with selumetinib and ABT-737, or to the three-drug combination (Fig. 6A). Immunoblotting demonstrated enhanced MAPK signaling in NRAS-mutated cells manifesting as high basal levels of p-ERK, in concert with a high expression of Mcl-1 (Fig. 6B). However, the suppression of p-ERK with selumetinib failed to markedly suppress Mcl-1, and it triggered only a modest induction of apoptosis as shown by the level of cleaved caspase-3. In turn, the combined selumetinib and AZD8055 further diminished the level of Mcl-1 in NRAS-mutant cells, and this combination paired with ABT-737 caused a marked decrease of Mcl-1 protein and triggered a discernible cleavage of caspase-3 (Fig. 6B). Furthermore, at low concentrations of three inhibitors, neither ABT-737 alone nor selumetinib/AZD8055 combination triggered the loss of Δψm. However, ABT-737 plus selumetinib and AZD8055 showed a major Δψm depolarization, which was even more pronounced in the NRAS-mutant cells (Fig. 6C), suggesting a critical role for mitochondrial-mediated apoptosis in the triple-drug combination–induced leukemia cell death, especially in the cells with NRAS mutations.

Figure 6.
Figure 6.

Mutated NRAS in AML cells are sensitive to selumetinib-induced apoptosis in the presence of ABT-737. A, MV4-11 cells with or without NRAS mutation were treated with AZD8055, selumetinib, or ABT-737, their combinations at the indicated concentrations (μmol/L) for 48 hours, and examined for apoptosis induction. Inset, basal phosphorylation level of p-MEK in wild-type (WT) and NRAS-mutated MV4-11 cells. *, P < 0.05; **, P < 0.01. B, NRAS-wild-type and NRAS-mutant MV4-11 cells were treated with the indicated drugs (μmol/L) for 16 hours, and corresponding protein expression was measured by immunoblotting. C, NRAS-wild type and -mutated MV4-11 cells were treated with the indicated drugs (μmol/L) for 24 hours, and loss of Δψm was evaluated using flow cytometry after staining with CMXRos and MitoTracker Green. **, P < 0.01.

Discussion

In this study, we tested the combination effects of the MEK inhibitor selumetinib and the mTOR inhibitor AZD8055 in human AML cells. Simultaneous inhibition of ERK and mTOR signaling by these agents led to an enhanced cytostatic effect in the OCI/AML3, MOLM13, and U937 cells. However, this treatment showed no synergistic effect in the KG-1 cells, which exhibit only trace basal levels of phospho-ERK and -AKT. Interestingly, we noticed that targeting MEK signaling with selumetinib drastically suppressed the p-S6K level in the OCI/AML3 and U937 cells, which was not accompanied by a decrease in the level of p-4E-BP1. The S6K and 4E-BP1 proteins are well-known mTOR substrates that contribute to cell proliferation and survival (26). S6K modulation by MAPK signaling is not well understood, although the PI3K/Akt and Ras/MAPK pathways are known to signal in a parallel manner to regulate Tsc1 and 2, and mediate the phosphorylation of S6K (27). Our data indicate that MEK/ERK signaling in conjunction with mTOR signaling plays a prominent role in regulating S6K activity in AML cells. However, the blockade of S6K activity alone is not the major predictor of cell sensitivity to MEK inhibition as exemplified by the vastly different mean half maximal inhibitory concentrations required for inhibiting the growth of OCI/AML3 cells (0.03 μmol/L; 95% confidence interval, CI, 0.01–0.08 μmol/L) and U937 cells (392 μmol/L; 95% CI, 0.5–2960 μmol/L; Supplementary Fig. S5) despite a similar suppression level of p-S6K. Conversely, mTOR inhibition not only activated MAPK signaling, which is reportedly dependent on a feedback loop of the S6K/PI3K/Ras pathway (14), but it also relieves the negative feedback loop, resulting in increased phosphorylation of AKT at Thr308 (28). Our findings support the notion that multiple circuitry feedback mechanisms are operational in these cells, and may also explain, at least in part, why the blockade of the AKT/mTOR/S6K axis had limited activity in phase I/II clinical trials in patients with hematologic malignancies (29).

The interaction and balance between pro- and antiapoptotic Bcl2 family proteins dictate cell fate (30). Bim is a positive effector of apoptosis induction and is involved in mitochondria-mediated apoptosis induction (31). Our previous studies demonstrated that upregulation of Bim expression, which triggers mitochondria-mediated apoptosis, plays a critical role in the antileukemia efficacy of Raf/MEK/ERK inhibitors (32). In the present study, we showed that selumetinib, or both selumetinib and AZD8055, markedly upregulated Bim expression, and that the further addition of ABT-737 enhanced this upregulation as well as apoptosis induction. In contrast, silencing the expression of Bim markedly diminished apoptosis induction by the agents.

The level of Mcl-1 is a predictive biomarker for sensitivity to therapy-induced apoptosis induction in a variety of hematopoietic malignancies, and its upregulation was mediated via ERK/Elk-1 or AKT/mTOR signaling (33, 34). Consistent with these reported findings, targeting of MEK or mTOR decreased Mcl-1 expression. Mcl-1 expression was further diminished in the presence of ABT-737, and resulted in enhanced apoptosis induction in AML cells. Moreover, lowering the Mcl-1 level by shRNA enhanced drug-induced apoptosis (Supplementary Fig. S7). Specifically, compared with NRAS wild-type MV4-11 cells, the NRAS-mutant MV4-11 cells expressed a higher basal level of Mcl-1 protein that was subsequently diminished by the combined targeting of MEK, mTOR, and Bcl-2 pathways to trigger apoptosis induction. Thus, the three-drug combination was much more effective against AML cells with NRAS mutations compared with those with wild-type NRAS.

The interaction of Bim with Mcl-1 interferes with the cytochrome c–releasing capability of Bim and protects cells against Bim-mediated apoptosis (35). The downregulation of Mcl-1 expression (or cleavage of Mcl-1) may lead to release of Bim from specific binding with Mcl-1 to trigger apoptosis. ERK-mediated phosphorylation of Bim EL (i.e., the extra-long spliced form of the Bim protein) promotes its proteasomal degradation (36), and phosphorylation of Mcl-1 slows this turnover (37). Furthermore, Akt-dependent glucose metabolism and ERK/ELK-1 activation promote Mcl-1 synthesis to maintain cell survival and differentiation (38, 39). Our findings suggest that the simultaneous suppression of PI3K/mTOR signaling and interference with Bcl-2 family protein dimerization are essential for drug-induced death of AML cells with a high AKT expression. A recent study using U937 cells indicated that the combination of PI3K/mTOR inhibitors with ABT-737 abrogated Bim binding to Bcl-2/Bcl-xL, which allowed Bim to activate Bax and Bak to exert proapoptotic activity (40). Recent studies indicate that leukemia stem cells (LSC) are characterized by relatively low levels of reactive oxygen species with an aberrant overexpression of BCL-2. Interestingly, the inhibition of BCL-2 reduced oxidative phosphorylation and selectively eradicated these quiescent LSCs (41). In our study, AML cells with high p-AKT and p-ERK levels (e.g., the MV4-11-NRAS–mutated cells) were efficiently killed by the triple-drug combination. This was accompanied by loss of Δψm indicating the high antileukemia potency of this treatment strategy against AML cells with gain-of-function NRAS mutations. This would also suggest a selective potency of this combination for targeting quiescent LSCs.

In summary, cotargeting the MEK and mTOR pathways may be an effective treatment strategy for patients who have AML cells that express high levels of MEK and mTOR, or in patients whose AML cells harbor NRAS mutations. This treatment may be further potentiated using the BH3 mimetic ABT-737. This three-drug combination could pave the way for the development of integrated therapeutic strategies that take advantage of the synergistic antileukemia effects, thereby leading to the design of novel, clinically viable combinations for AML therapy.

Disclosure of Potential Conflicts of Interest

P. Smith has ownership interest in AstraZeneca PLC. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: W. Zhang, M. Konopleva

Development of methodology: W. Zhang, W. Bornmann

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W. Zhang, V.R. Ruvolo, C. Gao, L. Zhou, W.D. Schober, M. Andreeff

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W. Zhang, V.R. Ruvolo, C. Gao, M. Konopleva, M. Andreeff

Writing, review, and/or revision of the manuscript: W. Zhang, P. Smith, M. Konopleva, M. Andreeff

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V.R. Ruvolo, P. Smith

Study supervision: M. Konopleva

Other (experimental work): T. Tsao

Other [provision of research materials (compounds) and advice on their use]: P. Smith

Other (contributed knowledge of the mTOR kinase inhibitor during critique and review of results): S. Guichard

Grant Support

This work was supported in part by grants from NIH/NCI (CA143805, CA100632, CA055164, and CA049639), a Cancer Center Support Grant (CA 16672, to M. Andreeff), and a Leukemia SPORE Career Development Award (CA100632-05, to W. Zhang).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors thank Wenjing Chen and Teresa McQueen who provided patient information and prepared patient samples for this study, AstraZeneca for providing selumetinib and AZD8055, and Numsen Hail, Jr. and Elizabeth L. Hess who provided critical reviews and editorial assistance to the authors during preparation of this article.

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

  • Received July 17, 2013.
  • Revision received March 25, 2014.
  • Accepted April 9, 2014.

References

  1. 1.↵
    1. Bacher U,
    2. Haferlach T,
    3. Schoch C,
    4. Kern W,
    5. Schnittger S
    . Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006;107:3847–53.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Illmer T,
    2. Thiede C,
    3. Fredersdorf A,
    4. Stadler S,
    5. Neubauer A,
    6. Ehninger G,
    7. et al.
    Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res 2005;11:3217–24.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Altman JK,
    2. Platanias LC
    . Prospects for mTOR targeting in adult T cell leukemia. Leuk Lymphoma 2009;50:525–6.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kornblau SM,
    2. Womble M,
    3. Qiu YH,
    4. Jackson CE,
    5. Chen W,
    6. Konopleva M,
    7. et al.
    Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006;108:2358–65.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Milella M,
    2. Kornblau SM,
    3. Estrov Z,
    4. Carter BZ,
    5. Lapillonne H,
    6. Harris D,
    7. et al.
    Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851–9.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Zeng Z,
    2. Sarbassov dD,
    3. Samudio IJ,
    4. Yee KW,
    5. Munsell MF,
    6. Ellen JC,
    7. et al.
    Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007;109:3509–12.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Zhang W,
    2. Konopleva M,
    3. Burks JK,
    4. Dywer KC,
    5. Schober WD,
    6. Yang JY,
    7. et al.
    Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res 2010;70:2424–34.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Yuan R,
    2. Kay A,
    3. Berg WJ,
    4. Lebwohl D
    . Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Milella M,
    2. Kornblau SM,
    3. Andreeff M
    . The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 2003;7:160–90.
    OpenUrlPubMed
  10. 10.↵
    1. Karakas T,
    2. Maurer U,
    3. Weidmann E,
    4. Miething CC,
    5. Hoelzer D,
    6. Bergmann L
    . High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998;9:159–65.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Samudio I,
    2. Konopleva M,
    3. Carter B,
    4. Andreeff M
    . Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res 2010;145:197–217.
    OpenUrlPubMed
  12. 12.↵
    1. Konopleva M,
    2. Contractor R,
    3. Tsao T,
    4. Samudio I,
    5. Ruvolo PP,
    6. Kitada S,
    7. et al.
    Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375–88.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Roberts AW,
    2. Seymour JF,
    3. Brown JR,
    4. Wierda WG,
    5. Kipps TJ,
    6. Khaw SL,
    7. et al.
    Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488–96.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Carracedo A,
    2. Ma L,
    3. Teruya-Feldstein J,
    4. Rojo F,
    5. Salmena L,
    6. Alimonti A,
    7. et al.
    Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065–74.
    OpenUrlPubMed
  15. 15.↵
    1. Oltersdorf T,
    2. Elmore SW,
    3. Shoemaker AR,
    4. Armstrong RC,
    5. Augeri DJ,
    6. Belli BA,
    7. et al.
    An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677–81.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Clodi K,
    2. Kliche K-O,
    3. Zhao S,
    4. Weidner D,
    5. Schenk T,
    6. Consoli U,
    7. et al.
    Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia (CLL) and expression of apoptosis-regulating genes. Cytometry 2000;40:19–25.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. ten Cati B,
    2. Samplonius DF,
    3. Bijma T,
    4. de Leij LF,
    5. Helfrich W,
    6. Bremer E
    . The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007;21:248–52.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Zhang W,
    2. McQueen T,
    3. Schober W,
    4. Rassidakis G,
    5. Andreeff M,
    6. Konopleva M
    . Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 2005;19:1977–84.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Ruvolo PP,
    2. Zhou L,
    3. Watt JC,
    4. Ruvolo VR,
    5. Burks JK,
    6. Jiffar T,
    7. et al.
    Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. J Cell Biochem 2011;112:1696–707.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Ruvolo VR,
    2. Karanjeet KB,
    3. Schuster TF,
    4. Brown R,
    5. Deng Y,
    6. Hinchcliffe E,
    7. et al.
    Role for PKC delta in fenretinide-mediated apoptosis in lymphoid leukemia cells. J Signal Transduct 2010;2010:584657.
    OpenUrlPubMed
  21. 21.↵
    1. Poot M,
    2. Pierce RH
    . Detection of changes in mitochondrial function during apoptosis by simultaneous staining with multiple fluorescent dyes and correlated multiparameter flow cytometry. Cytometry 1999;35:311–7.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Chou TC
    . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440–6.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Kim DH,
    2. Sabatini DM
    . Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol 2004;279:259–70.
    OpenUrlPubMed
  24. 24.↵
    1. Konopleva M,
    2. Milella M,
    3. Ruvolo P,
    4. Watts JC,
    5. Ricciardi MR,
    6. Korchin B,
    7. et al.
    MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2012;26:778–87.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. van Delft MF,
    2. Wei AH,
    3. Mason KD,
    4. Vandenberg CJ,
    5. Chen L,
    6. Czabotar PE,
    7. et al.
    The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389–99.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Meyuhas O,
    2. Dreazen A
    . Ribosomal protein S6 kinase from TOP mRNAs to cell size. Prog Mol Biol Transl Sci 2009;90:109–53.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Ma L,
    2. Chen Z,
    3. Erdjument-Bromage H,
    4. Tempst P,
    5. Pandolfi PP
    . Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179–93.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Das F,
    2. Ghosh-Choudhury N,
    3. Dey N,
    4. Mandal CC,
    5. Mahimainathan L,
    6. Kasinath BS,
    7. et al.
    Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase. J Biol Chem 2012;287:3808–22.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Yee KW,
    2. Zeng Z,
    3. Konopleva M,
    4. Verstovsek S,
    5. Ravandi F,
    6. Ferrajoli A,
    7. et al.
    Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12:5165–73.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Adams JM,
    2. Cory S
    . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324–37.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Bouillet P,
    2. Metcalf D,
    3. Huang DC,
    4. Tarlinton DM,
    5. Kay TW,
    6. Kontgen F,
    7. et al.
    Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735–8.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Zhang W,
    2. Konopleva M,
    3. Ruvolo VR,
    4. McQueen T,
    5. Evans RL,
    6. Bornmann WG,
    7. et al.
    Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808–18.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Booy EP,
    2. Henson ES,
    3. Gibson SB
    . Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011;30:2367–78.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Mills JR,
    2. Hippo Y,
    3. Robert F,
    4. Chen SM,
    5. Malina A,
    6. Lin CJ,
    7. et al.
    mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 2008;105:10853–8.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Han J,
    2. Goldstein LA,
    3. Gastman BR,
    4. Froelich CJ,
    5. Yin XM,
    6. Rabinowich H
    . Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J Biol Chem 2004;279:22020–9.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Luciano F,
    2. Jacquel A,
    3. Colosetti P,
    4. Herrant M,
    5. Cagnol S,
    6. Pages G,
    7. et al.
    Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003;22:6785–93.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Domina AM,
    2. Vrana JA,
    3. Gregory MA,
    4. Hann SR,
    5. Craig RW
    . MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004;23:5301–15.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Coloff JL,
    2. Macintyre AN,
    3. Nichols AG,
    4. Liu T,
    5. Gallo CA,
    6. Plas DR,
    7. et al.
    Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res 2011;71:5204–13.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Townsend KJ,
    2. Zhou P,
    3. Qian L,
    4. Bieszczad CK,
    5. Lowrey CH,
    6. Yen A,
    7. et al.
    Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. J Biol Chem 1999;274:1801–13.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Rahmani M,
    2. Aust MM,
    3. Attkisson E,
    4. Williams DC Jr.,
    5. Ferreira-Gonzalez A,
    6. Grant S
    . Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a. Cancer Res 2013;73:1340–51.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Lagadinou ED,
    2. Sach A,
    3. Callahan K,
    4. Rossi RM,
    5. Neering SJ,
    6. Minhajuddin M,
    7. et al.
    BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013;12:329–41.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Molecular Cancer Therapeutics: 13 (7)
July 2014
Volume 13, Issue 7

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
Weiguo Zhang, Vivian R. Ruvolo, Chen Gao, Liran Zhou, William Bornmann, Twee Tsao, Wendy D. Schober, Paul Smith, Sylvie Guichard, Marina Konopleva and Michael Andreeff
Mol Cancer Ther July 1 2014 (13) (7) 1848-1859; DOI: 10.1158/1535-7163.MCT-13-0576
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement